Sekisui Chemical Co., Ltd.

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Tohoku University

Yanmar Co., Ltd.

Nagoya Institute of Technology

Nb Health Laboratory Co., Ltd.

Marine Biotechnology Institute Co., Ltd.

Ne Health Laboratory Co., Ltd.

Joe Chiba

Masahiro Furutani

Koichiro Iwasa

Akihiro Uenishi

Naoki Nishiguchi

Kazuya Suzuki

Kiyoshi Takayama

Tomoko Shimizu

Tatsuo Shimizu

Akiyoshi Hirayama

Jun-ichi Hata

Junichi Hata

Akiko Togi

Stefan Jennewein

Rainer Fischer

Ryoichi Hagiwara

Seiji Takahashi

Kazuteru Toshinaga

Toru Takemoto

Yasuyuki Kori

Takefumi Shimoyama

Kana Matsushima

Kazufumi Kawabata

Jun-Ichi Hata

Stefan Gaida

Christopher Mcelroy

Provided is a recombinant cell that produces isoprene or terpene, wherein the recombinant cell includes an ability to synthesize isopentenyl diphosphate through a mevalonate pathway (MVA pathway), wherein the recombinant cell lacks an ability to synthesize isopentenyl diphosphate through an endogenous non-mevalonate pathway (MEP pathway), wherein the recombinant cell includes an isoprene synthase gene or a terpene synthase gene as a foreign gene, and wherein the recombinant cell produces, with the expression of the foreign gene, isoprene or terpene having 10, 15, 20, 30, or 40 carbon atoms. The mevalonate pathway is preferably an exogenous mevalonate pathway.

Recombinant cell, method for producing recombinant cell, and method for producing isoprene or terpene

An object of the present invention is to provide a series of techniques for producing 1,4-butanediol from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding at least one enzyme selected from the group consisting of succinate semialdehyde dehydrogenase, succinyl-CoA synthase, CoA-dependent succinate semialdehyde dehydrogenase, 4-hydroxybutyrate dehydrogenase, 4-hydroxybutyryl-CoA transferase, 4-hydroxybutyryl-CoA reductase, 4-hydroxybutyraldehyde dehydrogenase, and alcohol dehydrogenase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing 1,4-butanediol from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide.

Recombinant cell, and method for producing 1,4-butanediol

To provide a series of techniques capable of producing isoprene from syngas or the like. Provided is a recombinant cell prepared by introducing a nucleic acid encoding isoprene synthase into a host cell having an isopentenyl diphosphate synthesis ability by a non-mevalonate pathway, wherein the nucleic acid is expressed in the host cell, and the recombinant cell is capable of producing isoprene from at least one C1 compound selected from the group consisting of carbon monoxide, carbon dioxide, formic acid, and methanol. As the host cell, abacterium or abacterium is exemplified. Also provided is a method for producing isoprene using the recombinant cell.

Recombinant cell, and method for producing isoprene

An object of the present invention is to provide a series of techniques for producing isoprene from methanol or the like. Provided is a recombinant cell prepared by introducing a gene encoding isoprene synthase, into a host cell which is a methylotroph, wherein the gene is expressed in the host cell, and the recombinant cell is capable of producing isoprene from at least one C1 compound selected from the group consisting of methane, methanol, methylamine, formic acid, formaldehyde, and formamide. Preferably, it has at least one C1 carbon assimilating pathway selected from the group consisting of a serine pathway, a ribulose monophosphate pathway, and a xylulose monophosphate pathway as a fixing pathway of formaldehyde. Also provided is a method for producing isoprene using the recombinant cell.

Recombinant cell and method for producing isoprene

To provide a series of techniques for obtaining &#x3b2;-phellandrene with high purity and in a large quantity. Provided is a recombinant cell capable of producing &#x3b2;-phellandrene, prepared by introducing at least one nucleic acid selected from the group consisting of a nucleic acid encoding geranyl pyrophosphate (GPP) synthase and a nucleic acid encoding neryl pyrophosphate (NPP) synthase, and a nucleic acid encoding &#x3b2;-phellandrene synthase into a host cell in such a manner that these nucleic acids are expressed in the host cell. Also provided is a method for producing &#x3b2;-phellandrene by culturing the recombinant cell to produce &#x3b2;-phellandrene in the recombinant cell.

Recombinant cell, and method for producing &#x3b2;-phellandrene

An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.

Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier

An engine ignition system and the like are provided, which reduce a required voltage and improve an ignition performance without any special electrical configuration. An ignition system is configured so that: to an auxiliary electrode is applied a voltage that is not more than a voltage applied between a center electrode and a ground electrode and that generates no spark discharge; the auxiliary electrode is positioned so that an electric field Efbetween the auxiliary electrode and the ground electrode or an electric field Efbetween the auxiliary electrode and the center electrode, which is generated by the applied voltage, is spread over the gap. A time for applying the voltage to the auxiliary electrode is controlled to include a time for applying the voltage between the center electrode and the ground electrode.

Ignition system and ignition plug that reduces the required voltage to sustain an engine, while improving ignition performance and combustability

It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includesGroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.

Method for immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma, and method for producing monoclonal antibody

The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.

Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody

This invention provides a recombinant protein expression system using a host and cell-free translation system, and is capable of universally expressing a large amount of any protein as soluble protein, while preventing toxicity in hosts, formation of inclusion bodies, and decompositions with proteases. Such may be achieved by expressing the desired protein as a fusion protein with chaperoning, such as about 60 kDa molecular chaperons, 60 kDa heat shock proteins, or thermosomes, and accommodating the desired protein inside of a stereostructure of a chaperonin. The present invention provides a process for producing a protein, which comprises transcribing and translating a gene containing a gene encoding the linked chaperonin subunits and a gene encoding a desired protein thereby synthesizing a fusion protein having the desired protein linked via a peptide linkage to the linked chaperonin subunits.

Process for production of a recombinant protein and a fusion protein

This invention provides a recombinant protein expression system using a host and cell-free translation system, and is capable of universally expressing a large amount of any protein as soluble protein, while preventing toxicity in hosts, formation of inclusion bodies, and decomposition with proteases. Such may be achieved by expressing the desired protein as a fusion protein with chaperonins, such as about 60 kDa molecular chaperones, 60 kDa heat shock proteins, or thermosomes, and accommodating the desired protein inside of a stereostructure of a chaperonin. The present invention provides a process for producing a protein, which comprises transcribing and translating a gene containing a gene encoding the linked chaperonin subunits and a gene encoding a desired protein thereby synthesizing a fusion protein having the desired protein linked via a peptide linkage to the linked chaperonin subunits.

Growing community of inventors

Tokyo, Japan

Masahiro Furutani